OBJECTIVE: Renin-angiotensin- @entity1369 system blockers are the preferred antihypertensive medications in @entity1 with @entity6 and prior @entity64 . This study aimed to compare the effects of @entity7774 -converting enzyme inhibitors (ACEIs) and @entity11502 receptor blockers (ARBs) in terms of major adverse @entity299 (MACEs) in @entity1 with @entity6 who survived @entity385 . METHODS: We conducted an observational, nationwide, propensity score-matched cohort study using Taiwan's National Health Insurance Research Database. @entity1 aged at least 20 years with @entity164 2 @entity6 who initiated ACEI (n=15 959) or @entity11882 (n=23 929) use within 90 days after discharge for first @entity385 between January 2000 and December 2011 were allocated to ACEI and @entity11882 groups, respectively. The primary outcomes were MACEs ( @entity583 , @entity385 , and @entity65 ). The secondary outcomes were hospitalization for @entity810 and @entity4144 . Intention-to-treat and as-treated models were used. RESULTS: Intention-to-treat analysis showed no significant difference between the ACEI and @entity11882 groups in the outcomes of MACEs [hazard ratio (HR), 0.99; 95% confidence interval (CI), 0.95-1.04], including @entity385 (HR, 1.01; 95% CI, 0.97-1.06), @entity583 (HR, 1.06; 95% CI, 0.95-1.18), and @entity65 (HR, 0.98; 95% CI, 0.91-1.06). As-treated analysis produced similar results. Additionally, the groups showed no difference in the risk of hospitalization for @entity810 or @entity4144 . CONCLUSION: Our study supports the hypothesis that the risks of MACEs and two additional secondary outcomes in @entity1 with @entity6 who survived @entity385 did not differ according to ACEI versus @entity11882 use.

Angiotensin-converting enzyme inhibitors, @entity11502 receptor blockers and the risk of major adverse @entity299 in @entity1 with XXXX and prior @entity64 : a nationwide study.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity64 :: ('MESH:D020521', 'Disease') :: ['stroke'] @entity1369 :: ('MESH:D000450', 'Chemical') :: ['aldosterone'] @entity583 :: ('MESH:D009203', 'Disease') :: ['myocardial infarction'] @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetes'] @entity7774 :: ('MESH:D000809', 'Chemical') :: ['angiotensin'] @entity4144 :: ('MESH:D006947', 'Disease') :: ['hyperkalemia'] @entity164 :: ('MESH:D017827', 'Disease') :: ['type'] @entity810 :: ('MESH:D058186', 'Disease') :: ['acute kidney injury'] @entity299 :: ('MESH:D006331', 'Disease') :: ['cardiac events'] @entity11882 :: ('OMIM:611809', 'Disease') :: ['ARB'] @entity65 :: ('MESH:D002318', 'Disease') :: ['cardiovascular mortality'] @entity11502 :: ('MESH:D000804', 'Chemical') :: ['angiotensin II'] @entity385 :: ('MESH:D002544', 'Disease') :: ['ischemic stroke']
@entity6 :: (MESH:D003920,Disease) :: ['diabetes']
